Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Role of the Astroglial Glutamate Exchanger xCT in Ventral Hippocampus in Resilience to Stress.

Nasca C, Bigio B, Zelli D, de Angelis P, Lau T, Okamoto M, Soya H, Ni J, Brichta L, Greengard P, Neve RL, Lee FS, McEwen BS.

Neuron. 2017 Oct 11;96(2):402-413.e5. doi: 10.1016/j.neuron.2017.09.020.

2.

Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.

Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R.

J Am Acad Dermatol. 2017 Jul;77(1):167-170. doi: 10.1016/j.jaad.2017.03.024. No abstract available.

PMID:
28619556
3.

Transient Activation of GABAB Receptors Suppresses SK Channel Currents in Substantia Nigra Pars Compacta Dopaminergic Neurons.

Estep CM, Galtieri DJ, Zampese E, Goldberg JA, Brichta L, Greengard P, Surmeier DJ.

PLoS One. 2016 Dec 30;11(12):e0169044. doi: 10.1371/journal.pone.0169044. eCollection 2016.

4.

Identification of neurodegenerative factors using translatome-regulatory network analysis.

Brichta L, Shin W, Jackson-Lewis V, Blesa J, Yap EL, Walker Z, Zhang J, Roussarie JP, Alvarez MJ, Califano A, Przedborski S, Greengard P.

Nat Neurosci. 2015 Sep;18(9):1325-33. doi: 10.1038/nn.4070. Epub 2015 Jul 27.

5.

Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.

Brichta L, Greengard P.

Front Neuroanat. 2014 Dec 15;8:152. doi: 10.3389/fnana.2014.00152. eCollection 2014. Review.

6.

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems.

Brichta L, Greengard P, Flajolet M.

Trends Neurosci. 2013 Sep;36(9):543-54. doi: 10.1016/j.tins.2013.06.003. Epub 2013 Jul 19. Review.

PMID:
23876424
7.

Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy.

Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, Naudi A, Portero-Otín M, Dacremont G, Cartier N, Wanders R, Kemp S, Mandel JL, Wirth B, Pamplona R, Aubourg P, Pujol A.

Hum Mol Genet. 2010 May 15;19(10):2005-14. doi: 10.1093/hmg/ddq082. Epub 2010 Feb 23.

PMID:
20179078
8.

Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophy.

Brichta L, Garbes L, Jedrzejowska M, Grellscheid SN, Holker I, Zimmermann K, Wirth B.

Hum Genet. 2008 Mar;123(2):141-53. doi: 10.1007/s00439-007-0455-7. Epub 2008 Jan 3.

PMID:
18172693
9.

Spinal muscular atrophy and therapeutic prospects.

Wirth B, Brichta L, Hahnen E.

Prog Mol Subcell Biol. 2006;44:109-32.

PMID:
17076267
10.

Spinal muscular atrophy: from gene to therapy.

Wirth B, Brichta L, Hahnen E.

Semin Pediatr Neurol. 2006 Jun;13(2):121-31. Review.

PMID:
17027862
11.

An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival.

Fyfe JC, Menotti-Raymond M, David VA, Brichta L, Schäffer AA, Agarwala R, Murphy WJ, Wedemeyer WJ, Gregory BL, Buzzell BG, Drummond MC, Wirth B, O'Brien SJ.

Genome Res. 2006 Sep;16(9):1084-90. Epub 2006 Aug 9.

12.

In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.

Hahnen E, Eyüpoglu IY, Brichta L, Haastert K, Tränkle C, Siebzehnrübl FA, Riessland M, Hölker I, Claus P, Romstöck J, Buslei R, Wirth B, Blümcke I.

J Neurochem. 2006 Jul;98(1):193-202.

13.

The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.

Riessland M, Brichta L, Hahnen E, Wirth B.

Hum Genet. 2006 Aug;120(1):101-10. Epub 2006 May 25.

PMID:
16724231
14.

In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate.

Brichta L, Holker I, Haug K, Klockgether T, Wirth B.

Ann Neurol. 2006 Jun;59(6):970-5.

PMID:
16607616
15.

Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number.

Wirth B, Brichta L, Schrank B, Lochmüller H, Blick S, Baasner A, Heller R.

Hum Genet. 2006 May;119(4):422-8. Epub 2006 Mar 1.

PMID:
16508748
16.

Pronounced conformational changes following agonist activation of the M(3) muscarinic acetylcholine receptor.

Han SJ, Hamdan FF, Kim SK, Jacobson KA, Brichta L, Bloodworth LM, Li JH, Wess J.

J Biol Chem. 2005 Jul 1;280(26):24870-9. Epub 2005 May 2.

17.

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.

Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B.

Hum Mol Genet. 2003 Oct 1;12(19):2481-9. Epub 2003 Jul 29.

PMID:
12915451
18.

Comparison of methods of preservation of cadaver kidneys.

Sterling WA, Pierce JC, Lee HM, Hume M, Lee BB, Brichta LF, Currier CB, Hasegawa A.

Transplant Proc. 1972 Dec;4(4):621-3. No abstract available.

PMID:
4566808
19.

Acquired tolerance for cardiac allografts.

Childs JW, Szentpetery S, Poulain HJ, Brichta LF, Vaughan DL, Monaco AP, Lower RR.

Surg Forum. 1972;23(0):204-6. No abstract available.

PMID:
4601072

Supplemental Content

Loading ...
Support Center